{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T16:26:54Z","timestamp":1649089614337},"reference-count":19,"publisher":"EDP Sciences","issue":"1-2","license":[{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"vor","delay-in-days":185,"URL":"https:\/\/www.edpsciences.org\/en\/authors\/copyright-and-licensing"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biologie Aujourd\u2019hui"],"published-print":{"date-parts":[[2019]]},"abstract":"<jats:p>Le traitement de la crise migraineuse repose actuellement sur les anti-inflammatoires non st\u00e9ro\u00efdiens (AINS) et les triptans, qui sont les deux seules classes pharmacologiques dont l\u2019efficacit\u00e9 th\u00e9rapeutique a \u00e9t\u00e9 d\u00e9montr\u00e9e avec un haut niveau de preuve dans cette indication. Ces deux classes pharmacologiques ne couvrent cependant pas tous les besoins th\u00e9rapeutiques des migraineux. Deux programmes de d\u00e9veloppement clinique m\u00e9ritent une attention particuli\u00e8re et concernent les antagonistes des r\u00e9cepteurs du CGRP et les agonistes du r\u00e9cepteur 5-HT<jats:sub>1F<\/jats:sub> de la s\u00e9rotonine. L\u2019approche prophylactique est un \u00e9l\u00e9ment capital du traitement de la migraine \u00e9pisodique qui concerne plus d\u2019un tiers des migraineux. Actuellement, cette approche prophylactique est possible au travers de plusieurs traitements pharmacologiques ayant un bon niveau de preuve dans cette indication et appartenant \u00e0 diverses classes pharmacologiques\u2009: b\u00eata-bloquants (propranolol, m\u00e9toprolol), anti\u00e9pileptiques (divalproate de sodium, topiramate, gabapentine), inhibiteurs calciques (flunarizine), antid\u00e9presseurs tricycliques et antagonistes s\u00e9rotoninergiques (pizotif\u00e8ne). L\u2019approche prophylactique peut \u00e9galement faire appel en seconde intention \u00e0 des mol\u00e9cules mises plus r\u00e9cemment sur le march\u00e9 mais dont le niveau de preuve dans cette indication est plus faible\u2009: v\u00e9rapamil, venlafaxine, lisinopril et candesartan. Enfin, il convient de ne pas oublier l\u2019utilisation d\u2019anciens traitements (ox\u00e9torone) toujours en usage dans certains pays (comme la France). Devant le manque de sp\u00e9cificit\u00e9, de nouveaux m\u00e9dicaments \u00e9mergent, les plus importants \u00e9tant les anticorps monoclonaux antagonistes du <jats:italic>Calcitonin Gene-Related Peptide<\/jats:italic> (CGRP), mais de nombreux autres sont en phase I ou II de recherche tels que les modulateurs de la fonction endoth\u00e9liale, les antagonistes orexinergiques, l\u2019ocytocine, les inhibiteurs non s\u00e9lectifs des phosphodiest\u00e9rases, les modulateurs des jonctions communicantes. Enfin, un futur plus lointain repose sur les neuropeptides hypothalamiques (<jats:italic>Pituitary Adenylate Cyclase-Activating Polypeptide<\/jats:italic>, PACAP\u2009; neuropeptide Y, NPY), les inhibiteurs de synth\u00e8se de l\u2019oxyde nitrique (NO) et les canaux ioniques activ\u00e9s par l\u2019acidit\u00e9 extracellulaire (ASIC, <jats:italic>Acid-Sensing Ion Channels<\/jats:italic>).<\/jats:p>","DOI":"10.1051\/jbio\/2019021","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T18:48:41Z","timestamp":1562352521000},"page":"59-64","source":"Crossref","is-referenced-by-count":2,"title":["Les avanc\u00e9es dans les traitements de crise et de fond de la maladie migraineuse"],"prefix":"10.1051","volume":"213","author":[{"given":"Dominique","family":"Valade","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"250","published-online":{"date-parts":[[2019,7,5]]},"reference":[{"key":"R1","unstructured":"Alder Biopharmaceuticals, Inc. (2017). A multicenter assessment of ALD403 in frequent episodic migraine. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02559895."},{"key":"R2","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ana.24534","volume":"78","author":"Buettner","year":"2015","journal-title":"Ann Neurol"},{"key":"R3","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1526-4610.2008.01326.x","volume":"49","author":"Cady","year":"2009","journal-title":"Headache"},{"key":"R4","first-page":"1","volume":"17","author":"Cao","year":"2014","journal-title":"Pain Physician"},{"key":"R5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1177\/0333102410392605","volume":"31","author":"Caproni","year":"2011","journal-title":"Cephalalgia"},{"key":"R6","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/0333102414544979","volume":"35","author":"Chabi","year":"2015","journal-title":"Cephalalgia"},{"key":"R7","unstructured":"Eli Lilly and Company. (2017). Evaluation of LY2951742 in the prevention of episodic migraine\u2009\u2013\u2009the EVOLVE-1 study. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02614183."},{"key":"R8","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"Goadsby","year":"2017","journal-title":"N Engl J Med"},{"key":"R9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.nbd.2014.10.022","volume":"74","author":"Hoffmann","year":"2015","journal-title":"Neurobiol Dis"},{"key":"R10","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s13311-018-0619-2","volume":"15","author":"Karsan","year":"2018","journal-title":"Neurotherapeutics"},{"key":"R11","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2147\/JPR.S116968","volume":"9","author":"Kwok","year":"2016","journal-title":"J Pain Res"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Lambru G., \nAndreou A.P., \nGuglielmetti M., \nMartelletti P. \n(2018). \nEmerging drugs for migraine treatment: An update. \nExpert Opin Emerg Drugs, PMID 30484333.","DOI":"10.1080\/14728214.2018.1552939"},{"key":"R13","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa030505","volume":"350","author":"Olesen","year":"2004","journal-title":"N Engl J Med"},{"key":"R14","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s13311-018-0614-7","volume":"15","author":"Pradhan","year":"2018","journal-title":"Neurotherapeutics"},{"key":"R15","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1111\/pme.12792","volume":"16","author":"Schwedt","year":"2015","journal-title":"Pain Med"},{"key":"R16","unstructured":"Teva Branded Pharmaceutical Products, R&D Inc. (2017). Efficacy and safety of 2 dose regimens of TEV-48125 versus placebo for the preventive treatment of episodic migraine. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02629861."},{"issue":"2","key":"R17","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/head.13082","volume":"57","author":"Tzabazis","year":"2017","journal-title":"Headache"},{"key":"R18","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s13311-018-0615-6","volume":"15","author":"Vila-Pueyo","year":"2018","journal-title":"Neurotherapeutics"},{"key":"R19","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/acn3.113","volume":"1","author":"Zagami","year":"2014","journal-title":"Ann Clin Transl Neurol"}],"container-title":["Biologie Aujourd'hui"],"original-title":[],"link":[{"URL":"https:\/\/www.biologie-journal.org\/10.1051\/jbio\/2019021\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T17:02:53Z","timestamp":1584637373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biologie-journal.org\/10.1051\/jbio\/2019021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":19,"journal-issue":{"issue":"1-2"},"alternative-id":["jbio190021"],"URL":"https:\/\/doi.org\/10.1051\/jbio\/2019021","relation":{},"ISSN":["2105-0678","2105-0686"],"issn-type":[{"value":"2105-0678","type":"print"},{"value":"2105-0686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}